Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
329276 | Neurobiology of Aging | 2011 | 4 Pages |
Abstract
Mutations in the Cu/Zn superoxide dismutase (SOD1), transactive response (TAR)-DNA binding protein (TARDBP) and fused in sarcoma (FUS) genes account for approximately 1 third of familial amyotrophic lateral sclerosis (ALS) cases. Mutations in these genes have been found in 1% to 2% of apparently sporadic cases. We present the first case of an ALS patient carrying a de novo missense mutation of the FUS gene (c.1561C>T, p.R521C). This report highlights the importance of screening ALS patients, both familial and sporadic, for FUS mutations and also suggests that de novo mutations is a relevant mechanism underlying sporadic neurodegenerative disease.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Adriano Chiò, Andrea Calvo, Cristina Moglia, Irene Ossola, Maura Brunetti, Luca Sbaiz, Shiao-lin Lai, Yevgeniya Abramzon, Bryan J. Traynor, Gabriella Restagno,